So far, MET exon 14 skipping mutations in lung cancer are emerging as the most robust predictive marker, and the clinical data suggest that both MET copy number and protein overexpression may have predictive value as well, but appropriate cut-offs still need to be established [10, 27, 28] MET exon 14 skipping mutations have also recently been reported in secondary glioblastoma with a frequency of ~ 14%, and at lower frequencies in primary glioblastoma and low-grade glioma [29]. This evidence concerns the gene MET and glioblastoma.